Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 387

The DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.

Molecular modeling in drug discovery

Open access
Adelusi, Temitope Isaac, Oyedele, Abdul-Quddus Kehinde, Boyenle, Ibrahim Damilare, Ogunlana, Abdeen Tunde, Adeyemi, Rofiat Oluwabusola, Ukachi, Chiamaka Divine, Idris, Mukhtar Oluwaseun, Olaoba, Olamide Tosin, Adedotun, Ibrahim Olaide, Kolawole, Oladipo Elijah, Xiaoxing, Yin, Abdul-Hammed, Misbaudeen·2022·Informatics in Medicine Unlocked

Abstract

With the financial requirements and high time associated with bringing a commercial drug to the market, the application of computer-aided drug design has been recognized as a powerful technology in the drug discovery pipeline. In accelerating drug discovery, molecular modeling techniques have experienced considerable growth in computational capabilities over the last decade. Pharmaceutical companies and academic research organizations are currently using various computational modeling techniques to lower the cost and time required for the discovery of an effective drug. In this article, we focus on reviewing three key components of molecular modeling (Molecular Docking, Molecular Dynamics, and ADMET modeling), their applications, and limitations in small-molecule drug discovery. We discussed the technicalities encircling molecular dynamics and docking, the algorithms used to develop the docking softwares, and the models explored by these algorithms coupled with their scoring functions. We also reviewed the influence of molecular dynamics simulations (all atoms and coarse-grained molecular dynamics simulations) in drug discovery and also elucidated how the ensembles generated from MD simulations could pave the way for novel drug discovery. Furthermore, we briefly explain the role played by pharmacokinetics and pharmacodynamics profiling in discovering new leads for therapeutic efficacy. Besides the computational success of molecular modeling in drug discovery, we highlighted the experimental corroboration of in silico discovered drug candidates. However, as there is hardly a drug in the market discovered primarily with the use of computational modeling, we concluded the review by proposing possible solutions that could foster the advancement and clinical success of drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.imu.2022.100880

Cites

207 of 207 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 207 references

Research works printed but not linked: 18

  1. Ferrè, 2004, SURFACE: a database of protein surface regions for functional annotation, Nucleic Acids Res, 32, D240, 10.1093/nar/gkh054 · doi:10.1093/nar/gkh054
  2. Chikhi, 2010, Real-time ligand binding pocket database search using local surface descriptors, Proteins, 78, 2007, 10.1002/prot.22715 · doi:10.1002/prot.22715
  3. Pereira, 2004, Structure of shikimate kinase from Mycobacterium tuberculosis reveals the binding of shikimic acid, Acta Crystallogr D Biol Crystallogr, 60, 2310, 10.1107/S090744490402517X · doi:10.1107/s090744490402517x
  4. Yang, 2000, Flexible ligand docking using a robust evolutionary algorithm, J Comput Chem, 21, 988, 10.1002/1096-987X(200008)21:11<988::AID-JCC8>3.0.CO;2-H · doi:10.1002/1096-987x(200008)21:11<988::aid-jcc8>3.0.co;2-h
  5. Taylor, 2002, A review of protein-small molecule docking methods, J Comput Aided Mol Des, 16, 151, 10.1023/A:1020155510718 · DOI · Paper page
  6. Briand, 2019, Combined ensemble docking and machine learning in identification of therapeutic agents with potential inhibitory effect on human CES1, Molecules, 24, 2747, 10.3390/molecules24152747 · doi:10.3390/molecules24152747
  7. Kandeel, 2018, Molecular dynamics and binding selectivity of nucleotides and polynucleotide substrates with EIF2C2/Ago2 PAZ domain, Int J Biol Macromol, 107, 2566, 10.1016/j.ijbiomac.2017.10.145 · doi:10.1016/j.ijbiomac.2017.10.145
  8. Peng, 2015, Insilico approaches in anesthetic drug development: computer aided drug designing, Drug Res, 65, 587
  9. Bao, 2018, Discover potential inhibitors for PFKFB3 using 3D-QSAR, virtual screening, molecular docking and molecular dynamics simulation, J Recept Signal Transduct Res, 38, 413, 10.1080/10799893.2018.1564150 · doi:10.1080/10799893.2018.1564150
  10. Toyoda, 1999, Development of MD engine: high-speed accelerator with parallel processor design for molecular dynamics simulations, J Comput Chem, 20, 10.1002/(SICI)1096-987X(19990130)20:2<185::AID-JCC1>3.0.CO;2-L · doi:10.1002/(sici)1096-987x(19990130)20:2<185::aid-jcc1>3.0.co;2-l
  11. de Oliveira, 2006, On the application of accelerated molecular dynamics to liquid water simulations, J Phys Chem B, 110, 22695, 10.1021/jp062845o · doi:10.1021/jp062845o
  12. Chen, 2009, Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase, J Med Chem, 52, 2716, 10.1021/jm8011905 · doi:10.1021/jm8011905
  13. Adelusi, 2021, Molecular docking assessment of clinically approved antiviral drugs against Mpro, spike glycoprotein and angiotensin converting enzyme-2 revealed probable anti-SARS-CoV-2 potential, Trop J Nat Prod Res, 5
  14. Sandhaus, 2018, Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays, Sci Rep, 8, 1437, 10.1038/s41598-018-19944-4 · doi:10.1038/s41598-018-19944-4
  15. Peiffer, 2021, TMPRSS2 inhibitor discovery facilitated through an in silico and biochemical screening platform, bioRxiv [Preprint]
  16. Theerawatanasirikul, 2020, Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses, Antivir Res, 182, 10.1016/j.antiviral.2020.104927 · doi:10.1016/j.antiviral.2020.104927
  17. Kaproń, 2019, Development of the 1,2,4-triazole-based anticonvulsant drug candidates acting on the voltage-gated sodium channels. Insights from in-vivo, in-vitro, and in-silico studies, Eur J Pharmaceut Sci, 129, 42, 10.1016/j.ejps.2018.12.018 · doi:10.1016/j.ejps.2018.12.018
  18. Singla, 2019, Stevia rebaudiana targeting α-amylase: an in-vitro and in-silico mechanistic study, Nat Prod Res, 33, 548, 10.1080/14786419.2017.1395433 · doi:10.1080/14786419.2017.1395433

Cited by

See all 387

Metadata

Authors
Adelusi, T. I., Oyedele, A.-Q. K., Boyenle, I. D., Ogunlana, A. T., Adeyemi, R. O., Ukachi, C. D., Idris, M. O., Olaoba, O. T., Adedotun, I. O., Kolawole, O. E., Xiaoxing, Y., & Abdul-Hammed, M.
Venue
Informatics in Medicine Unlocked
Publisher
Elsevier BV
Published
2022
Volume
29
Pages
100880
ISSN
2352-9148 (ISSN-L)
OpenAlex
W4211216582
Cited by
387
References
207
FWCI
39.40
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular modeling in drug discovery. https://app.cochat.ai/papers/10.1016/j.imu.2022.100880
The paper
Adelusi, T. I., Oyedele, A.-Q. K., Boyenle, I. D., Ogunlana, A. T., Adeyemi, R. O., Ukachi, C. D., Idris, M. O., Olaoba, O. T., Adedotun, I. O., Kolawole, O. E., Xiaoxing, Y., & Abdul-Hammed, M. (2022). Molecular modeling in drug discovery. Informatics in Medicine Unlocked. https://doi.org/10.1016/j.imu.2022.100880

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.